By promoting CTL infiltration and inhibiting MDSCs while efficiently polarizing MDSCs toward the M1 phenotype to lower tumor burden, low‐dose DTX increased the effectiveness of anti‐PD‐L1 antibody, and ultimately improved the anti‐tumor efficacy (Figure 11C).[113]. This evidence concerns the gene CD274 and neoplasm.